Model Type: Non-human primate

  • Primate model of dyskinesia

    Model Overview Marmosets or macaques, previously rendered parkinsonian by MPTP administration, are administered twice-daily L-DOPA (25 mg/kg/day p.o.) over a 12-week period until the development of dyskinesia. Stable and robust dyskinesia can be maintained over several years by regular administration of L-DOPA. The model can be applied to examine effects of treatment on the development…

  • MPTP-lesioned non-human primate

    Model Overview MPTP (0.2 mg/kg, i.v.) is administered to cynomolgus macaques over a period of several weeks and titrated to produce the required severity of parkinsonian phenotype. The degree of parkinsonism is stable and persists over many years allowing both the acute and chronic effect of compounds to be evaluated.  Dopamine agonists reverse MPTP-induced parkinsonism…